Ilmarinen Mutual Pension Insurance Co lifted its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 19.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,530 shares of the medical technology company’s stock after acquiring an additional 9,500 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Stryker were worth $15,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE bought a new stake in Stryker in the second quarter valued at approximately $1,404,284,000. Legal & General Group Plc bought a new position in Stryker during the 2nd quarter worth approximately $707,212,000. Jupiter Topco LLC acquired a new position in shares of Stryker in the 2nd quarter worth approximately $681,581,000. Corient Private Wealth LP acquired a new position in shares of Stryker in the 2nd quarter worth approximately $323,035,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Stryker in the 2nd quarter valued at $464,506,000. 77.09% of the stock is owned by institutional investors and hedge funds.
Stryker Stock Down 1.0%
Stryker stock opened at $309.91 on Friday. The company has a market capitalization of $117.98 billion, a PE ratio of 33.00, a PEG ratio of 2.13 and a beta of 0.78. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The firm’s fifty day moving average is $295.66 and its 200 day moving average is $321.39. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same period last year, the firm posted $3.19 earnings per share. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. As a group, sell-side analysts predict that Stryker Corporation will post 14.85 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Ronda Stryker sold 550,000 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the transaction, the director directly owned 1,701,375 shares of the company’s stock, valued at approximately $553,491,315. This represents a 24.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.60% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on SYK. Wells Fargo & Company lowered their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Jefferies Financial Group cut their price target on shares of Stryker from $440.00 to $405.00 and set a “buy” rating on the stock in a research report on Tuesday, September 22nd. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a report on Wednesday, October 7th. BTIG Research lifted their price objective on Stryker from $304.00 to $345.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Rothschild & Co Redburn dropped their price objective on Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Twenty-one investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $343.77.
Get Our Latest Stock Report on SYK
Stryker Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
See Also
- Five stocks we like better than Stryker
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
